Logo
x

Search category

Subscribe Now

US FDA

Insights+: The US FDA New Drug Approvals in October 2022

Insights+: The US FDA New Drug Approvals in October 2022

  • November 17, 2022
Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval as an Adjuvant Therapy for Renal Cell Carcinoma

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval as an Adjuvant Therapy for Renal Cell Carcinoma

  • November 19, 2021
Coherus and Junshi's Toripalimab Receive the US FDA's Orphan Drug Designation for the Treatment of Esophageal Cancer

Coherus and Junshi's Toripalimab Receive the US FDA's Orphan Drug Designation for the Treatment of Esophageal Cancer

  • November 16, 2021
Novartis' Scemblix (asciminib) Receives the US FDA's Approval for the Treatment of Chronic Myeloid Leukemia

Novartis' Scemblix (asciminib) Receives the US FDA's Approval for the Treatment of Chronic Myeloid Leukemia

  • October 29, 2021
Regeneron and Sanofi's Dupixent (dupilumab) Receive the US FDA's Approval as an Add-On Maintenance Treatment to Treat Moderate-To-Severe Asthma

Regeneron and Sanofi's Dupixent (dupilumab) Receive the US FDA's Approval as an Add-On Maintenance Treatment to Treat Moderate-To-...

  • October 21, 2021
Janssen Report Submission of sBLA to the US FDA for the Approval of Stelara (ustekinumab) to Treat Juvenile Psoriatic Arthritis

Janssen Report Submission of sBLA to the US FDA for the Approval of Stelara (ustekinumab) to Treat Juvenile Psoriatic Arthritis

  • October 11, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.